|
Canada-804904-Midwives ไดเรกทอรีที่ บริษัท
|
ข่าว บริษัท :
- Aripiprazole - Mechanism of Action and Side Effects - Psych Scene Hub
Aripiprazole is a partial dopamine (D2) agonist with a high affinity for the D2 receptor but lower intrinsic activity at the D2 receptor than dopamine (DA) It is classified as a Dopamine System Stabiliser (DSS) due to its ability to modulate DA levels in key brain pathways
- Receptor Binding Profiles of Atypical Antipsychotics:
An antipsychotic’s binding profile is a summation of the receptors to which it binds, the strength of the binding to individual receptor types (binding affinity or Ki), and the action of the drug on that receptor type (antagonism, partial agonism, etc )
- Mechanism of action of brexpiprazole: comparison with aripiprazole . . .
The relative affinities of brexpiprazole and aripiprazole for the 5HT1A receptor are highlighted with a gray arrow moving to the left, indicating that brexpiprazole has substantially more potent 5HT1A receptor binding affinity than aripiprazole
- Aripiprazole: Pharmacodynamics, Pharmacokinetics and Adverse Effects
Aripiprazole's pharmacodynamics are distinguished by its selective receptor binding profile Aripiprazole exhibits a high affinity for dopamine receptors, with a Ki value of 0 74 nmol L, indicating a stronger binding than many other antipsychotic drugs, except for risperidone
- Aripiprazole - PubMed
Aripiprazole is a new chemical entity with a unique pharmacological profile It has strong affinities for certain dopamine receptors, and intermediate affinity for serotonin, adrenergic and histamine receptors
- Update on the Mechanism of Action of Aripiprazole: Translational . . .
However, the receptor profile of the compound is much more complex, and animal models have shown that aripiprazole affects multiple cellular pathways and several cortical and subcortical neurotransmitter circuitries and has an impact on gene expression distinct from other antipsychotics
- A Systematic Review of Aripiprazole—Dose, Plasma Concentration . . .
Aripiprazole is an atypical antipsychotic with a unique pharmacologic profile, acting as a partial agonist at dopa-mine D2 receptors, an antagonist at 5-HT2A receptors, and a partial agonist at 5-HT1A receptors 2,3 Attempts have been made to establish a dose-response range for aripiprazole4,5 but little is known about plasma-level relationships
- Aripiprazole: an appraisal of the translation of complex receptor . . .
evidence suggests that aripiprazole may have a role in the treatment of mood disorders The efficacy side-effect profile of aripiprazole is reviewed herein Aripiprazole is the newest agent in a class of med-ications that are now called Second Generation Antipsychotics (SGAs) Its receptor pharma-cology differs from other SGAs [1] Based upon
- Aripiprazole: a review of its pharmacology and clinical use
Aripiprazole is a new atypical antipsychotic with a unique receptor binding profile that combines partial agonist activity at D2 and 5HT1A receptors with potent antagonism at 5HT2A receptors Clinical studies in acute schizophrenic relapse, chronic schizophrenia and acute mania show it is robustly more effective than placebo
|
|